235 results on '"Cortes, Jorge E."'
Search Results
2. Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.
3. Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study.
4. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
5. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
6. Navigating disparities: Insights from a colorectal cancer screening program in federally qualified community healthcare centers.
7. Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?
8. Characteristics of Cancer Survivors Living in Poverty in the United States: Results From the 2020 Behavioral Risk Factor Surveillance System Survey
9. Antibody seroprevalence against SARS-Cov-2 among chronic myeloid leukemia patients.
10. Bosutinib (BOS) in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, effusion, and renal safety characterization in the BFORE trial.
11. Treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) following the discontinuation of tyrosine kinase inhibitors.
12. Are pivotal clinical trials for lymphomas that led to drug approval representative of the population affected by these diseases?
13. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update.
14. Demographic disparities in genomic data and clinical trials for multiple myeloma.
15. Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.
16. OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).
17. The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
18. Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib.
19. Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.
20. Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).
21. Effect of early blood counts on overall survival (OS) following glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis.
22. Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.
23. An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.
24. A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies.
25. Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure: ≥8-y update of a phase I/II study.
26. Geographic disparity of outcome in patients with cancer over decades: The surveillance, epidemiology, and end results.
27. Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.
28. Germline Genetic Predisposition to Myeloid Neoplasia From GATA2 Gene Mutations: Lessons Learned From Two Cases
29. First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study.
30. Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.
31. Clinical value of event-free survival (EFS) in acute myeloid leukemia (AML).
32. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
33. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia.
34. Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP).
35. Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML).
36. Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.
37. Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia.
38. IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study.
39. Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.
40. Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP).
41. Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.
42. Granulocyte transfusions in patients with skin and soft tissues infections and leukemia: Are they useful?
43. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
44. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
45. Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.
46. Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.
47. Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes.
48. Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3-ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment.
49. Characteristics and outcomes of myelodysplastic syndrome (MDS) with chromosome (chr)3q abnormalities.
50. Association of early intervention in transfusion independent (TI) patients (Pts) with lower-risk myelodysplastic syndromes (MDS) treated with attenuated doses of hypomethylating agents (HMAs) with high response rates and long duration of response.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.